Clovis Oncology

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLVS and other ETFs, options, and stocks.

About CLVS

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. 

CEO
Patrick J. Mahaffy
CEOPatrick J. Mahaffy
Employees
413
Employees413
Headquarters
Boulder, Colorado
HeadquartersBoulder, Colorado
Founded
2009
Founded2009
Employees
413
Employees413

CLVS Key Statistics

Market cap
160.37M
Market cap160.37M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
6.61M
Average volume6.61M
High today
$1.18
High today$1.18
Low today
$1.10
Low today$1.10
Open price
$1.13
Open price$1.13
Volume
2.06M
Volume2.06M
52 Week high
$4.91
52 Week high$4.91
52 Week low
$0.581
52 Week low$0.581

CLVS Earnings

-$0.77
-$0.51
-$0.26
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 2, Pre-Market
ActualExpected Nov 2, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.